Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Millan MJ.

Neurotherapeutics. 2009 Jan;6(1):53-77. doi: 10.1016/j.nurt.2008.10.039. Review.

2.

Monoamine neurocircuitry in depression and strategies for new treatments.

Hamon M, Blier P.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:54-63. doi: 10.1016/j.pnpbp.2013.04.009. Epub 2013 Apr 19. Review.

PMID:
23602950
3.

[Antidepressants, stressors and the serotonin 1A receptor].

Kirilly E, Gonda X, Bagdy G.

Neuropsychopharmacol Hung. 2015 Jun;17(2):81-9. Review. Hungarian.

4.

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.

Kasper S, Hamon M.

World J Biol Psychiatry. 2009;10(2):117-26. doi: 10.1080/15622970902717024. Review.

PMID:
19255935
5.

The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.

Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Poeggeler B, Hardeland R, Cardinali DP.

World J Biol Psychiatry. 2009;10(4 Pt 2):342-54. doi: 10.1080/15622970701625600. Review.

PMID:
18609422
6.

[Efficacy of atypical antipsychotics in depressive syndromes].

Quintin P, Thomas P.

Encephale. 2004 Nov-Dec;30(6):583-9. Review. French.

PMID:
15738862
7.

Agomelatine versus other antidepressive agents for major depression.

Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M.

Cochrane Database Syst Rev. 2013 Dec 17;(12):CD008851. doi: 10.1002/14651858.CD008851.pub2. Review.

PMID:
24343836
8.

[Fluoxetine: an update of its use in major depressive disorder in adults].

Gourion D, Perrin E, Quintin P.

Encephale. 2004 Jul-Aug;30(4):392-9. Review. French.

PMID:
15597466
9.

[Mechanism of action of antidepressants and therapeutic perspectives].

Bourin M, David DJ, Jolliet P, Gardier A.

Therapie. 2002 Jul-Aug;57(4):385-96. Review. French.

PMID:
12422559
11.

On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal.

Millan MJ.

Int J Neuropsychopharmacol. 2014 Jul;17(7):1009-37. doi: 10.1017/S1461145712001496. Epub 2013 May 30. Review.

PMID:
23719026
12.

Duloxetine pharmacology: profile of a dual monoamine modulator.

Karpa KD, Cavanaugh JE, Lakoski JM.

CNS Drug Rev. 2002 Winter;8(4):361-76. Review.

13.

Agomelatine: innovative pharmacological approach in depression.

Popoli M.

CNS Drugs. 2009;23 Suppl 2:27-34. doi: 10.2165/11318640-000000000-00000. Review.

PMID:
19708723
14.

Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors.

Guiard BP, El Mansari M, Blier P.

Curr Drug Targets. 2009 Nov;10(11):1069-84. Review.

PMID:
19702555
15.

Antidepressant drug development: Focus on triple monoamine reuptake inhibition.

Lane RM.

J Psychopharmacol. 2015 May;29(5):526-44. doi: 10.1177/0269881114553252. Epub 2014 Oct 14. Review.

PMID:
25315829
16.

Treating each and every depressed patient.

Kennedy SH.

J Psychopharmacol. 2008 Sep;22(7 Suppl):19-23. doi: 10.1177/0269881108093270. Review.

PMID:
18753279
17.

Oestrogen: an overlooked mediator in the neuropsychopharmacology of treatment response?

Keating C, Tilbrook A, Kulkarni J.

Int J Neuropsychopharmacol. 2011 May;14(4):553-66. doi: 10.1017/S1461145710000982. Epub 2010 Sep 22. Review.

PMID:
20860875
18.

[Interest of the use of pindolol in the treatment of depression: review].

Brousse G, Schmitt A, Chereau I, Eschalier A, Dubray C, Llorca PM.

Encephale. 2003 Jul-Aug;29(4 Pt 1):338-50. Review. French.

PMID:
14615704
20.

Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms?

Adell A.

Curr Drug Targets CNS Neurol Disord. 2004 Apr;3(2):113-21. Review. Erratum in: Curr Drug Targets CNS Neurol Disord. 2004 Jun;3(3)269.

PMID:
15078186

Supplemental Content

Support Center